MS Treatment Options: DMTs, Biologics, and Emerging Therapies

Relapsing MS treatment options fall into three groups of disease-modifying therapies (DMTs): injectables (interferon beta, glatiramer acetate and the self-injected antibody ofatumumab), oral drugs (fumarates, S1P receptor modulators, teriflunomide and cladribine) and infusions (natalizumab, ocrelizumab and alemtuzumab). In their pivotal trials the high-efficacy antibodies cut relapse rates by roughly 50 to 70 percent, against about 30 percent for interferons and glatiramer acetate, and ocrelizumab is the only DMT approved for primary progressive MS [7, 12].

How MS Treatments Work

Multiple sclerosis disease-modifying therapies change the course of the disease rather than end it. They reduce the frequency and severity of relapses, slow the accumulation of new lesions on MRI, and delay long-term disability progression. They do not repair existing damage.

The distinction between symptomatic treatments (managing fatigue, pain, spasticity) and disease-modifying treatments (altering the disease course) is important. The sections below cover disease-modifying therapies; symptomatic management is a separate conversation with your neurologist [1].

Most DMTs act on the immune system in one of four ways: they rebalance immune signaling (interferons, glatiramer acetate), keep immune cells out of the central nervous system (natalizumab, S1P modulators), slow the division of activated lymphocytes (teriflunomide, cladribine), or remove B cells altogether (the anti-CD20 antibodies ocrelizumab, ofatumumab and ublituximab). The American Academy of Neurology practice guideline recommends offering a DMT to people with relapsing MS who have had recent relapses or MRI activity [1].

Injectable DMTs: The First Generation

Interferons

Agents: Interferon beta-1a (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia), peginterferon beta-1a (Plegridy)

Interferons were the first FDA-approved MS treatments (1993). They reduce relapse rates by approximately 30% compared to placebo. Their mechanism involves modulation of immune cell trafficking and cytokine balance [2].

Advantages: Decades of safety data. Well-understood side effect profile. Plegridy offers the convenience of every-2-week dosing.

Limitations: Flu-like symptoms after injection (fever, myalgia, fatigue) affect most patients initially. Injection site reactions with subcutaneous formulations. Modest efficacy compared to newer therapies. Liver function monitoring required. Neutralizing antibodies can develop and reduce efficacy over time.

Interferons remain available but have largely been replaced by more effective options as first-line therapy.

Glatiramer Acetate (Copaxone, Glatopa)

Glatiramer acetate is a synthetic peptide mixture that mimics myelin basic protein, shifting immune responses from pro-inflammatory Th1 toward regulatory pathways. It reduces relapse rates by approximately 30%.

Advantages: A long and reassuring safety record. No lab monitoring required. No serious immunosuppression. Available as a 3-times-weekly (40 mg) or once-daily (20 mg) injection. Generic available (Glatopa).

Limitations: Injection site reactions (lipoatrophy with long-term use). Modest efficacy. Daily or thrice-weekly injections.

Oral DMTs

Dimethyl Fumarate (Tecfidera) and Diroximel Fumarate (Vumerity)

Fumarates activate the Nrf2 antioxidant pathway and shift immune cell populations. They reduce relapse rates by approximately 50% and significantly reduce new MRI lesions, according to the DEFINE trial led by Ralf Gold (2012) [3].

Advantages: Oral twice-daily dosing. Good efficacy. Vumerity has improved GI tolerability over Tecfidera.

Limitations: GI side effects (flushing, nausea, diarrhea, abdominal pain) are common, especially in the first month. Lymphopenia monitoring required. Rare risk of progressive multifocal leukoencephalopathy (PML) with sustained lymphocyte counts below 500.

Fingolimod (Gilenya) and Siponimod (Mayzent)

Sphingosine-1-phosphate (S1P) receptor modulators trap lymphocytes in lymph nodes, preventing them from entering the CNS. Fingolimod reduces relapse rates by 48-54% versus placebo, according to the FREEDOMS trial (2010) [4].

Advantages: Once-daily oral dosing. Fingolimod has long track record (approved 2010). Siponimod specifically studied in secondary progressive MS (EXPAND trial showed disability benefit) [13].

Limitations: First-dose cardiac monitoring required (risk of bradycardia). Macular edema screening. Rebound disease activity if discontinued abruptly. Varicella immunity must be confirmed before starting. Wash-out period needed before pregnancy.

Newer S1P modulators (ozanimod/Zeposia, ponesimod/Ponvory) offer similar mechanisms with potentially fewer first-dose cardiac effects.

Teriflunomide (Aubagio)

Teriflunomide is an inhibitor of dihydroorotate dehydrogenase that reduces pyrimidine synthesis in rapidly dividing lymphocytes. It reduces relapse rates by approximately 30-36%, according to the TEMSO trial led by Paul O’Connor (2011) [14]. The dose is 7 mg or 14 mg by mouth once daily.

Advantages: Once-daily oral dosing. Well-tolerated long term.

Limitations: Hair thinning in 10-15% of patients (usually transient). Liver function monitoring. Teratogenic with very long half-life (requires accelerated elimination procedure with cholestyramine if pregnancy is planned). Modest efficacy compared to newer oral agents.

Cladribine (Mavenclad)

Cladribine is a purine nucleoside analog that selectively depletes lymphocytes. It is given as short oral courses (10 days in year 1, 10 days in year 2), then no treatment for years 3-4 while immune reconstitution occurs.

Advantages: Treatment-free intervals (immune reconstitution therapy model). High efficacy (relapse rate reduction 55-58%). No daily medication after dosing periods. Convenient for patients who want breaks from therapy [5].

Limitations: Lymphopenia (expected and intentional). Herpes zoster risk. Theoretical malignancy concern (not confirmed in clinical data to date). Not suitable for severely immunocompromised patients.

Infusion Therapies (High-Efficacy)

Natalizumab (Tysabri)

Natalizumab is a monoclonal antibody against alpha-4 integrin that blocks immune cell migration across the blood-brain barrier. It is one of the most effective DMTs available, reducing relapse rates by 68% and new MRI lesions by 83%, according to the AFFIRM trial led by Chris Polman (2006) [6].

Advantages: Extremely effective. Once-monthly IV infusion of 300 mg (or extended interval dosing every 6 weeks in JCV-negative patients). Rapid onset of action.

Limitations: Risk of progressive multifocal leukoencephalopathy (PML) in JCV antibody-positive patients. PML risk is highest with JCV index above 1.5, prior immunosuppressant use, and treatment duration beyond 2 years. Requires JCV antibody monitoring every 6 months. Severe rebound activity if discontinued without bridging to another DMT.

Ocrelizumab (Ocrevus)

Ocrelizumab is an anti-CD20 monoclonal antibody that depletes B lymphocytes. It was the first therapy approved for both relapsing MS and primary progressive MS (PPMS).

Efficacy: 46-47% relapse rate reduction versus interferon beta-1a in OPERA trials [7]. For PPMS (ORATORIO trial), 24% reduction in disability progression versus placebo [12].

Advantages: Every-6-month IV infusion of 600 mg after two starting doses of 300 mg given two weeks apart. Only approved therapy for PPMS. B-cell depletion is highly effective at suppressing new inflammatory activity. Subcutaneous formulation (Ocrevus SC) now approved for faster administration.

Limitations: Infusion reactions (common, usually manageable with pre-medication). Reduced vaccine responses. Hepatitis B reactivation risk (screening required). Long-term infection risk with prolonged B-cell depletion. Hypogammaglobulinemia can develop with extended use.

Ofatumumab (Kesimpta)

Ofatumumab is another anti-CD20 antibody, but delivered as a monthly subcutaneous self-injection rather than IV infusion. It reduces relapse rates by 50-59% versus teriflunomide in the ASCLEPIOS trials led by Stephen Hauser (2020) [8].

Advantages: At-home self-injection (no infusion center visits). Same mechanism and similar efficacy to ocrelizumab. Monthly dosing with autoinjector pen: 20 mg at weeks 0, 1 and 2, then 20 mg every month from week 4.

Limitations: Injection site reactions. Same B-cell depletion concerns as ocrelizumab (vaccine responses, infection risk, hypogammaglobulinemia with long-term use).

Alemtuzumab (Lemtrada)

Alemtuzumab is an anti-CD52 antibody that causes profound immune cell depletion followed by reconstitution. It is given as two treatment courses (5 days in year 1, 3 days in year 2).

Efficacy: 49-55% relapse rate reduction versus interferon in CARE-MS trials. High rates of “no evidence of disease activity” (NEDA).

Limitations: Significant secondary autoimmunity risk (thyroid disease in 30-40%, immune thrombocytopenia in 1-2%, rare anti-GBM nephropathy). Requires 48 months of monthly monitoring after each course. Reserved for highly active disease due to safety profile [9].

How Injectable, Oral and Infusion MS Treatments Compare

Injectable, oral and infusion DMTs differ most in mechanism, in how often you take them and in how much they lower relapse rates. Interferon beta and glatiramer acetate lower relapses by about 30 percent, the oral drugs by about 30 to 58 percent, and the antibodies by about 50 to 70 percent.

Route of delivery is a poor guide to strength. Ofatumumab is an injection yet sits in the high-efficacy group with the infusions, while teriflunomide is a pill with efficacy close to the interferons. Cross-trial comparisons are approximate, because the trials used different comparators (placebo, interferon or teriflunomide).

Lab Monitoring for MS Treatments

Lab monitoring is part of every MS treatment plan except glatiramer acetate. Neurologists use blood tests and screening to catch liver injury, low lymphocyte counts, infection risk and secondary autoimmunity early, and the schedule depends on the drug class.

What lab monitoring does Aubagio (teriflunomide) need?

Aubagio needs liver tests, a blood count and pregnancy screening, according to the US prescribing information. Before the first dose, your neurologist checks transaminases (ALT) and bilirubin from the past six months, a complete blood count, a tuberculosis screen, blood pressure, and a pregnancy test for anyone who could become pregnant. ALT is then checked at least monthly for the first six months.

Teriflunomide stays in the body for a long time: its plasma half-life is about 18 to 19 days, and without help it can take many months, sometimes up to two years, to fall below the 0.02 mg/L level considered safe for pregnancy. The accelerated elimination procedure uses cholestyramine 8 g every 8 hours, or activated charcoal 50 g every 12 hours, for 11 days, followed by two blood tests at least 14 days apart.

Treatment Options for Progressive MS

Progressive MS has fewer treatment options than relapsing MS. Ocrelizumab is the only DMT approved for primary progressive MS, based on the ORATORIO trial led by Xavier Montalban (2017), which showed a 24% lower risk of confirmed disability progression versus placebo [12].

For secondary progressive MS (SPMS), the picture depends on whether the disease is still active. Siponimod reduced confirmed disability progression in the EXPAND trial (Kappos, 2018), and the FDA label for most relapsing-MS DMTs covers active SPMS with ongoing relapses or new MRI lesions [13]. For non-active progressive MS, evidence for any DMT is thin, and care leans on rehabilitation, symptom management and trials of pipeline drugs.

Treatment Strategy: Escalation vs Early High-Efficacy

Traditionally, neurologists started with a moderate-efficacy agent (interferon or glatiramer acetate) and escalated to higher-efficacy therapies only after breakthrough disease. This “escalation” approach prioritized safety but allowed disability to accumulate before intensifying treatment.

The field is shifting toward early high-efficacy treatment (EHT), starting with potent therapies like natalizumab, ocrelizumab, or ofatumumab at diagnosis. Multiple retrospective studies show that patients started on high-efficacy therapy within the first year have less disability at 5-10 years than those who escalated [10].

The decision between approaches depends on:

• Disease activity: Highly active disease at presentation (multiple relapses, many MRI lesions, spinal cord involvement) favors early high-efficacy treatment
• Patient age and risk tolerance: Younger patients have more to lose from accumulated disability and may benefit most from aggressive early treatment
• Family planning: Pregnancy considerations influence DMT choice and timing. Glatiramer acetate and natalizumab have the most pregnancy data. Most other DMTs require washout before conception.
• JCV status: JCV positivity limits natalizumab use to shorter durations

The choice is made with an MS neurologist and revisited at follow-up MRIs; a new relapse or new lesions on a moderate-efficacy drug is the usual reason to switch.

Emerging Therapies

BTK Inhibitors

Bruton’s tyrosine kinase (BTK) inhibitors are the most anticipated pipeline therapy class for MS. Unlike anti-CD20 antibodies (which deplete B cells), BTK inhibitors modulate B-cell and microglial function without depletion. This makes them potentially effective against both the inflammatory and neurodegenerative components of MS.

Four BTK inhibitors reached phase III trials: tolebrutinib, fenebrutinib, evobrutinib, and remibrutinib. The relapsing-MS results have been mixed. Evobrutinib (EVOLUTION trials, 2023) and tolebrutinib (GEMINI 1 and 2, 2024) did not lower relapse rates more than teriflunomide, and evobrutinib’s development in MS was stopped. Tolebrutinib’s HERCULES trial in non-relapsing secondary progressive MS did delay confirmed disability progression versus placebo (2024). Regulatory decisions and fenebrutinib and remibrutinib readouts are still arriving, so ask your neurologist about current status.

Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

aHSCT involves ablating the immune system with chemotherapy and reconstituting it with the patient’s own stem cells. In highly selected patients with aggressive relapsing MS, it produces NEDA rates of 68-83% at 5 years, superior to any approved DMT [11]. It is increasingly used in specialized centers but carries treatment-related mortality of 0.3-1% and significant short-term morbidity.

aHSCT, a hospital procedure run by hematology and neurology teams, is different from the mesenchymal stem cell infusions sold at cash-pay clinics: the FDA has not approved those products for MS, and controlled evidence for them is limited. Our overview of stem cell therapy for MS explains the difference, and the stem cell therapy treatment guide covers how these products are regulated.

Where Integrative and Regenerative Clinics Fit

Disease-modifying therapies are prescribed and monitored by neurologists, and they remain the foundation of MS care. Integrative and regenerative clinics work alongside that care with services such as nutrition, rehabilitation or IV and oxygen therapies. Evidence for most of these add-ons in MS is thin, most are cash pay, and none replaces a DMT.

If you want to compare providers, the national list of clinics offering MS treatment shows who offers which services, and the multiple sclerosis treatment guide summarizes the evidence for each approach. Regenerated.com is free for patients, listing order is not paid ranking, Featured slots are labeled and capped, and Verified means credential checks rather than spend, as the guide to Featured, Verified and organic listings explains. Inclusion in the directory is not an endorsement, so bring any plan back to your neurologist. For the condition itself, see the multiple sclerosis condition page, and for one of the most common symptoms, our piece on MS fatigue.

Frequently asked questions

What are the treatment options for relapsing MS?

Relapsing MS is treated with disease-modifying therapies in three groups: injectables such as interferon beta, glatiramer acetate and ofatumumab; oral drugs such as dimethyl fumarate, fingolimod, teriflunomide and cladribine; and infusions such as natalizumab, ocrelizumab and alemtuzumab. The high-efficacy antibodies lowered relapse rates by roughly 50 to 70 percent in their pivotal trials. Your neurologist matches the drug to disease activity, age, pregnancy plans and JCV status, alongside steroids for acute relapses and symptom care.

How often do you need blood tests on Aubagio?

Aubagio (teriflunomide) needs liver tests at least monthly for the first six months, according to the US prescribing information. Before starting, your neurologist checks ALT and bilirubin, a complete blood count, tuberculosis screening, blood pressure and, where relevant, a pregnancy test. After the first six months, liver tests and blood counts continue at intervals your neurologist sets, and symptoms such as jaundice, dark urine or fever should be reported promptly.

What is the half-life of Kesimpta?

Kesimpta (ofatumumab) has a half-life of about 16 days at steady state, according to its US prescribing information. Its effect lasts much longer than the drug itself, because B cells it removes take several months to repopulate after the last dose. That is why vaccines are ideally given before starting, and why infection risk and pregnancy planning are discussed for months after stopping rather than weeks.

Does Kesimpta cause diarrhea?

Diarrhea is not one of the most common side effects of Kesimpta (ofatumumab). In the ASCLEPIOS trials, the most frequent reactions were upper respiratory infections, injection-related reactions such as fever and headache, injection site reactions and urinary tract infections. Because anti-CD20 drugs lower B cells, new or lasting diarrhea, especially with fever, can signal an infection and is worth reporting to your neurologist rather than treating at home.

What is the most effective MS treatment?

The most effective approved MS treatments are the high-efficacy antibodies: natalizumab, the anti-CD20 drugs ocrelizumab and ofatumumab, and alemtuzumab. In pivotal trials they lowered relapse rates by roughly 50 to 70 percent. Outside approved drugs, aHSCT produced NEDA rates of 68 to 83 percent at five years in highly selected patients, at the cost of higher procedural risk. The most effective option for one person also depends on safety, JCV status and pregnancy plans.

Related Reading

• Multiple Sclerosis: The Evidence-Based Guide (Pillar)
• Early Signs of Multiple Sclerosis: What to Watch For
• MS Diet: What the Research Actually Shows
• Multiple Sclerosis Symptoms: Early Signs and Progression

Sources

1. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777-788. doi:10.1212/WNL.0000000000005347 ↩
2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655-661. doi:10.1212/WNL.43.4.655 ↩
3. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107. doi:10.1056/NEJMoa1114287 ↩
4. Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401. doi:10.1056/NEJMoa0909494 ↩
5. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416-426. doi:10.1056/NEJMoa0902533 ↩
6. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910. doi:10.1056/NEJMoa044397 ↩
7. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-234. doi:10.1056/NEJMoa1601277 ↩
8. Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546-557. doi:10.1056/NEJMoa1917246 ↩
9. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis. Lancet. 2012;380(9856):1819-1828. doi:10.1016/S0140-6736(12)61769-3 ↩
10. Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175-187. doi:10.1001/jama.2018.20588 ↩
11. Muraro PA, Martin R, Mancardi GL, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol. 2017;13(7):391-405. doi:10.1038/nrneurol.2017.81 ↩
12. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209-220. doi:10.1056/NEJMoa1606468 ↩
13. Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273. doi:10.1016/S0140-6736(18)30475-6 ↩
14. O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303. doi:10.1056/NEJMoa1014656 ↩